Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transtympanic sodium thiosulfate gel for prevention of cisplatin-induced hearing loss
NL-OMON47112Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sodium thiosulfate in cisplatin-induced ototoxicity and Hypoacusis (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Occurrence of ototoxicity by audiometry. Started Jun 2013; status: active, not recruiting.
02
Drugs
sodium thiosulfate
03
Conditions
cisplatin-induced ototoxicityHypoacusis
Beyond the preview
Go deeper on NL-OMON47112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47112.